Deerfield Management Company L.P. Series C Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Deerfield Management Company L.P. Series C bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 9,298 shares of the company’s stock, valued at approximately $1,400,000.

Other hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new position in TransMedics Group in the 2nd quarter valued at about $47,000. J.Safra Asset Management Corp boosted its position in TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the period. Signaturefd LLC lifted its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Fidelis Capital Partners LLC purchased a new stake in shares of TransMedics Group during the 1st quarter worth $35,000. Finally, Amalgamated Bank raised its stake in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TMDX shares. TD Cowen boosted their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Stephens upped their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Needham & Company LLC started coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Piper Sandler boosted their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $174.30.

Insider Buying and Selling at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now owns 8,893 shares of the company’s stock, valued at $1,353,514.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,948,714.31. The disclosure for this sale can be found here. Insiders have sold a total of 61,247 shares of company stock worth $9,650,880 over the last ninety days. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Trading Down 4.9 %

Shares of TMDX stock opened at $148.28 on Thursday. The company has a market cap of $4.95 billion, a P/E ratio of -436.12 and a beta of 1.99. The stock has a 50 day simple moving average of $156.02 and a two-hundred day simple moving average of $130.77. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. Research analysts forecast that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.